Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC–Potsdam Cohort Study

Abstract

Omentin is a novel biomarker shown to exert metabolic, inflammatory, and immune-related properties and thereby could be implicated in the risk of colorectal cancer. So far, the association between omentin and colorectal cancer risk has not been evaluated in prospective cohort studies. We investigated the association between prediagnostic plasma omentin concentrations and risk of colorectal cancer in a case-cohort comprising 251 incident colorectal cancer cases diagnosed over a mean follow-up time of 10.4 years and 2,295 persons who remained free of cancer in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Hazard ratios as a measure of relative risk (RR) and 95% confidence intervals (CI) were computed using a Prentice-modified Cox regression. In a multivariable model adjusted for age, sex, education, dietary and lifestyle factors, body mass index (BMI), and waist circumference, higher omentin concentrations were associated with a higher colorectal cancer risk (RR continuously per doubling of omentin concentrations ¼ 1.98; 95% CI, 1.45-2.73). Additional adjustment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive protein, did not alter the results. In stratified analyses, the positive association between omentin and colorectal cancer risk was retained in participants with BMI < 30 (RR continuously per doubling of omentin concentrations ¼ 2.26; 95% CI, 1.57-3.27), whereas among participants with BMI ! 30 no association was revealed (RR continuously per doubling of omentin concentrations ¼ 1.07; 95% CI, 0.63-1.83; P interaction ¼ 0.005). These novel findings provide the first lines of evidence for an independent association between prediagnostic omentin concentrations and colorectal cancer risk and suggest a potential interaction with the adiposity state of the individual. Cancer Res; 76(13); 3862-71. Ó2016 AACR.

Association of Chemerin Plasma Concentration With Risk of Colorectal Cancer

“… 42 Several proinflammatory molecules secreted in adipose tissue and implicated in immune and metabolic pathways have also been associated with CRC, including adiponectin (particularly its non–high-molecular-weight form), soluble leptin receptor, and omentin. 43 , 44 , 45 Our results showing a positive association between chemerin concentration and CRC support those lines of research implicating involvement of immune-inflammatory pathways in colorectal carcinogenesis. While the exact mechanisms explaining the biological association are unclear, several pathways could have a role and be consistent with systemically elevated chemerin concentrations.…”

Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma

“…Both colorectal and pancreatic cancers are related with obesity, metabolic syndrome and BMI. Recently clinical studies show that cancers such as liver [10], prostate [12] and colorectal [11], [13], [16] are associated with increases in omentin serum levels independent of various factors such as BMI, glucose, lipid parameters, disease differentiation [16]. In a new study, higher omentin concentrations were associated with a higher colorectal cancer risk independent of obesity [16].…”

Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal Carcinogenesis

“…These findings indicate that intelectin-1 functions as a tumor suppressor in gastrointestinal cancers. In contrast, Aleksandrova et al reported that a higher intelectin-1 concentration was associated with a higher colorectal cancer risk in a prospective cohort study [72]. These controversial findings may reflect the “ Janus -faced” pathobiological properties of intelectin-1 in various types of carcinogenesis.…”